Skip to main content
OpenTrials
Completed

NCT Number: NCT03896048

Continuous Measurement of Diaphragm Excursion as a Predictor of Extubation Failure

Background: Patients are put under invasive mechanical ventilation (MV) during respiratory failure because they can no longer breathe in a way that delivers enough oxygen to their body. MV involves placing a tube into the wind pipe that is attached to a machine (known as a ventilator) which helps the patient breathe. However, MV is associated with complications such as shrinkage and damage of the diaphragm muscle fibres. It has been shown that the diaphragm (the main breathing muscle which provides approximately 70% of the work in healthy persons) can be affected after only 3-4 days of MV. Disconnection from the ventilator (a process known as extubation) is conducted with the calculated risk that the patient may become exhausted due to the additional workload of breathing off the ventilator resulting in needing to be reconnected to the ventilator (a process known as reintubation). Reintubation requires additional deep sedation of the patient and leads to longer time connected to the ventilator, increased risk of new lung infections, prolonged stay in the intensive care unit (ICU) and further immobilisation. Thus, the intensive care physician must constantly evaluate the need for MV to maintain adequate breathing versus withdrawal as quickly as possible to reduce the risk associated with long-term use of MV. However, to date, there is no technique for continuous assessment of diaphragm function that can be easily used at the patient's bedside. RESPINOR DXT, which offers continuous ultrasound monitoring of the right diaphragm velocity without the need of the continued presence of an operator, could offer an interesting solution.

Aim: The primary objective of this study is to compare diaphragm excursion values obtained around a 30-minute SBT using RESPINOR DXT in patients who are successfully and unsuccessfully extubated. Data analysis will be performed using post-processing. The timepoints to be analysed will be:

* Pre-SBT: 10, 30 and 60 minutes before the start of the SBT * During the 30-minute SBT: 0, 1, 2, 3, 4, 10, 20 and 30 minutes * Post-SBT: 5, 10, 20, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24, 48 hours after the end of the 30-minute SBT.

Hypothesis: The investigators hypothesise that there will be significantly different median diaphragm excursion between successful and failed extubation groups in at least one of the timepoints of interest. The information from this pilot study will be used to design a fully-powered observational study.

Primary outcome: Median diaphragm excursion

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

St Olav's Hospital

Trondheim, Norway

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Older than 17 years,
  • At least 24 hours and maximum of 7 days of invasive controlled mechanical ventilation prior to commencing pressure support ventilation,
  • A minimum 30-minute SBT is planned to be initiated by the ICU physicians in charge on or before the 14th day of MV, before extubation is considered,
  • The reason for admission to the ICU is adequately treated and the general condition is steadily improving, defined as reduction of general supportive ICU therapy, e.g. fluid supplements, cardiovascular stabilising medications, sedative agents, oxygen supply below 50% and mechanical ventilator support,
  • Informed consent to participate in the study from patient or the close relative/next to kin.

Exclusion criteria

  • Central or spinal neurological injury influencing central ventilation or its transmission, including critical illness neuropathy and myopathy,
  • Diagnosed chronic neuromuscular disease prior to admission,
  • Administration of neuromuscular blocking agents within the previous 24 hours,
  • Known paralysis of a hemidiaphragm or suspicion of paralysis of a hemidiaphragm, defined by the radiographic evidence of elevation of a dome >2.5 cm compared to the contralateral dome,
  • Patient with therapeutic limitation, i.e. reduced expectancy to survive,
  • Women known to be pregnant,
  • Protected adult who is not legally responsible and has a legal guardian,
  • Skin damage or dressing at the subcostal area at the site of the probe placement.

Treatment and study plan

Primary outcomes

  1. Differences in median diaphragm excursion between patients who are successfully and unsuccessfully extubated

    Time frame: Up to 48 hours post-extubation

Secondary outcomes

  1. Differences in maximum diaphragm excursion between patients who are successfully and unsuccessfully extubated

    Time frame: Up to 48 hours post-extubation

  2. Thresholds for diaphragm excursion, rapid shallow breathing index (RSBI) and modified RSBI (m-RSBI) to predict extubation or weaning outcome at selected timepoints

    Time frame: Up to 48 hours post-extubation

    Thresholds for continuous diaphragm excursion, RSBI and m-RSBI will be defined by receiver operating characteristic (ROC) curve analysis to predict extubation failure. The sensitivity, specificity, positive and negative predictive value as well as the area under the ROC curves (AUROC) will be presented

  3. Differences in median diaphragm excursion between patients who are successfully and unsuccessfully weaned

    Time frame: Up to 48 hours post end of SBT

    Failed weaning will be defined as a patient who fails extubation, fails the SBT or who is not extubated following a successful SBT

  4. Differences in maximum diaphragm excursion between patients who are successfully and unsuccessfully weaned

    Time frame: Up to 48 hours post end of SBT

Sponsors and collaborators

Lead sponsor

Respinor AS

Industry

Collaborators

  • European Commission

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Mar 29, 2019
Registry last updated
Jun 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.